Maxim Group analyst Jason McCarthy maintained a Buy rating on IntelGenx Technologies (IGXT) today and set a price target of $2. The company’s shares opened today at $0.60, close to its 52-week low of $0.51.
McCarthy commented:
“IntelGenx announced that it has begun dosing patients for the Phase 2a study of Montelukast VersaFilm in mild to moderate Alzheimer’s disease (AD). The primary endpoints are efficacy and safety. The trial will enroll patients at 8 clinical sites in Canada.”
According to TipRanks.com, McCarthy has 0 stars on 0-5 star ranking scale with an average return of -2.2% and a 34.3% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, ContraVir Pharmaceuticals Inc, and Sonoma Pharmaceuticals Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for IntelGenx Technologies with a $1.75 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $1.83 and a one-year low of $0.51. Currently, IntelGenx Technologies has an average volume of 903.2K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
IntelGenx Technologies Corp. engages in the development of novel oral immediate-release and controlled-release products for the pharmaceutical market. Its products include rizaport, tadalafil, loxapine, and montelukast.
